Loading...
•
Dec 31, 2021
Terns Q4 2021 Earnings Report
Terns reported financial results for the fourth quarter and full year ended December 31, 2021, and provided corporate highlights.
Key Takeaways
Terns Pharmaceuticals reported its Q4 and full year 2021 financial results, highlighting the expected top-line data readout from the TERN-201 clinical trial in NASH in March 2022, and the planned initiation of the Terns' first NASH trial of TERN-501 alone and in combination with TERN-101 in the first half of 2022.
Top-line data from TERN-201 (VAP-1 inhibitor) clinical trial in NASH is expected in March 2022.
Terns plans to initiate its first NASH trial of TERN-501 (THR-β agonist) alone and in combination with TERN-101 (FXR agonist) in the first half of 2022.
TERN-601 (GLP-1 receptor agonist) development candidate was nominated with the goal of initiating a first-in-human clinical trial in 2023.
Cash and equivalents of $166 million provides runway into 2024.
Terns
Terns
Forward Guidance
Terns anticipates continuing momentum with top-line data from the AVIATION trial of TERN-201 in NASH patients and plans to initiate the first Phase 2a trial of TERN-501 alone and in combination with TERN-101 in NASH patients.
Positive Outlook
- Top-line data from AVIATION Trial Part 1 (10 mg) and Part 2 (20 mg) expected in March 2022 and the second half of 2022, respectively.
- TERN-501 demonstrated significant, dose-dependent effects on sex hormone binding globulin (SHBG).
- TERN-501 was generally well-tolerated.
- TERN-101 treatment led to study population shifts to cT1 categories associated with lower risk of clinical events in chronic liver disease patients
- TERN-601 candidate nominated at year-end 2021 as an oral, small-molecule GLP-1 receptor agonist targeting metabolic diseases such as obesity and NASH with the potential for once-daily dosing